Viridian Therapeutics, Inc.DE
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc.DE insiders filed 0 open-market purchases and 1 sale; 216 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $342.6M (483.6% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Jan 19, 2024 | Mar 8, 2023 | Mar 10, 2022 |
| Revenue | $70.8M | $302.0K | $314.0K | $1.77M | $2.96M |
| Operating expenses | $434.2M | $299.3M | $254.8M | $136.1M | $82.7M |
| Research and development | $338.9M | $238.3M | $159.8M | $100.9M | $56.9M |
| Selling, general and administrative | $95.3M | $61.1M | $95.0M | $35.2M | $25.8M |
| Operating income | -$363.4M | -$299.0M | -$254.4M | -$134.3M | -$79.7M |
| Interest expense | – | – | – | $500.0K | – |
| Income tax | $0 | – | – | – | – |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M | -$79.4M |
| EPS, basic | – | – | $-5.31 | $-4.05 | $-6.66 |
| EPS, diluted | – | – | $-5.31 | $-4.05 | $-6.66 |
| Weighted shares, basic | – | – | 44.8M | 32.1M | 11.9M |
| Weighted shares, diluted | – | – | 44.8M | 32.1M | 11.9M |
| Margins and growth | |||||
| Operating margin | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% |
| Net margin | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% |
| Revenue growth, year over year | +23,359.9% | −3.8% | −82.3% | −40.2% | +182.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Jan 19, 2024 | Mar 8, 2023 | Mar 10, 2022 |
| Short-term investments | – | – | – | – | $154.7M |
| Total current assets | $894.2M | $738.5M | $486.5M | $431.2M | $200.2M |
| Property, plant and equipment | $1.23M | $1.24M | $1.67M | $1.33M | $375.0K |
| Total assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M |
| Accounts payable | $8.68M | $2.14M | $2.24M | $14.2M | $2.33M |
| Total current liabilities | $70.7M | $47.9M | $26.6M | $33.3M | $13.6M |
| Long-term debt | – | $20.6M | $20.2M | $4.64M | – |
| Total liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M |
| Shareholders' equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Jan 19, 2024 | Mar 8, 2023 | Mar 10, 2022 |
| Operating cash flow | -$276.4M | -$232.3M | -$184.2M | -$93.8M | -$54.6M |
| Capital expenditures | $495.0K | $511.0K | $898.0K | $797.0K | $338.0K |
| Free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | -$54.9M |
| Depreciation and amortization | $460.0K | $540.0K | $522.0K | $255.0K | $120.0K |
| Stock-based compensation | $44.3M | $42.1M | $67.2M | $19.8M | $14.5M |
| Investing cash flow | -$37.6M | -$228.7M | -$94.3M | -$115.1M | -$74.3M |
| Financing cash flow | $426.7M | $457.7M | $225.7M | $322.2M | $125.3M |
| Net change in cash | $112.8M | -$3.23M | -$52.8M | $113.3M | -$3.60M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 62.5% | 13957.0% | 21392.4% | 1115.4% | 488.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 113.6M | +19.0% | SEC |
| Aug 3, 2026 | 113.3M | +38.7% | SEC |
| May 1, 2026 | 103.1M | +26.3% | SEC |
| Feb 20, 2026 | 102.2M | +25.4% | SEC |
| Oct 31, 2025 | 95.4M | +20.5% | SEC |
| Aug 1, 2025 | 81.7M | +27.8% | SEC |
| May 1, 2025 | 81.6M | +27.8% | SEC |
| Feb 20, 2025 | 81.5M | +29.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.